Efficacy News and Research

RSS

Kessler Foundation scientists receive more than $1.2 M grants from NJ Commission for SCI research

The New Jersey Commission on Spinal Cord Injury Research awarded three grants to scientists at Kessler Foundation. The grants, which exceed $1.2 million, fund studies of assisted walking with Ekso, the impact of aging in the population with spinal cord injury (SCI) and the effects of electrical stimulation on bone loss.

10 Jul 2013

Glythera secures £700k to advance development of new generation of biological therapeutics

Glythera Ltd is delighted to announce that it has successfully achieved a number of technical and commercial milestones which has resulted in the release of a second tranche of funding totalling £700k from IP Group and its managed fund, the Finance for Business North East Technology Fund.

9 Jul 2013

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient's immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute's inception, exploring the close relationship between the immune system and cancer has been one of the Institute's priority research areas.

9 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

Probiodrug AG (Probiodrug) announced that it will be making two poster and two oral presentations at the upcoming Alzheimer's Association International Conference in Boston, MA July 13 - 18, 2013.

8 Jul 2013

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Oncologist urges drug companies to include key information in cancer drug labels

In the July 10th issue of The New England Journal of Medicine, Dr. Basch calls for pharmaceutical manufacturers to collect rigorous information on how drugs impact symptoms and quality of life starting early in drug development, and for the U.S. Food and Drug Administration (FDA) to include this information in drug labels.

5 Jul 2013

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen Idec nd Swedish Orphan Biovitrum AB (publ) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE for hemophilia A.

4 Jul 2013

Prana gets Austin HREC approval for 12-month open label extension study of PBT2 in Alzheimer’s patients

Prana Biotechnology today announced that it has received approval from the Austin Health Human Research Ethics Committee (HREC) to commence a 12-month open label extension study with Alzheimer’s Disease patients participating in Prana’s IMAGINE trial.

4 Jul 2013

Updated EULAR recommendations for management of rheumatoid arthritis

The European League Against Rheumatism has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs should be initiated as soon as a diagnosis of RA is made, with the aim of reaching a target of remission or low disease activity in every patient.

4 Jul 2013

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia.

4 Jul 2013

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer related death by 34% over five years compared to surgery alone, researchers said at the 15th ESMO World Congress in Gastrointestinal Cancer.

4 Jul 2013

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

University of Adelaide research has produced a potential new antibiotic which could help in the battle against bacterial resistance to antibiotics.

4 Jul 2013

Telemonitoring with pharmacist management improves and maintains BP control

An intervention that consisted of home blood pressure (BP) telemonitoring with pharmacist management resulted in improvements in BP control and decreases in BP during 12 months, compared with usual care, and improvement in BP that was maintained for 6 months following the intervention, according to a study in the July 3 issue of JAMA.

3 Jul 2013

Imaxio receives FP7 grant to support the development of S. aureus vaccine

Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project’ consortium to develop a vaccine against Staphylococcus aureus (S. aureus).

3 Jul 2013

Study says screening heart with natriuretic peptide may reduce risk of dysfunction, heart failure

Among patients at risk of heart failure, collaborative care based on screening for certain levels of brain-type natriuretic peptide reduced the combined rates of left ventricular systolic dysfunction, diastolic dysfunction, and heart failure as well as emergency cardiovascular hospitalizations, according to a study in the July 3 issue of JAMA.

3 Jul 2013

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.

3 Jul 2013

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Twelve residents and medical students each received a one-year, $40,000 National Psoriasis Foundation fellowship to study psoriasis and psoriatic arthritis.

3 Jul 2013

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.

3 Jul 2013

Efficacy News and Research

Kessler Foundation scientists receive more than $1.2 M grants from NJ Commission for SCI research

Glythera secures £700k to advance development of new generation of biological therapeutics

Cancer immunotherapies promise to be a new tool in fight against cancer

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Oncologist urges drug companies to include key information in cancer drug labels

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Prana gets Austin HREC approval for 12-month open label extension study of PBT2 in Alzheimer’s patients

Updated EULAR recommendations for management of rheumatoid arthritis

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

Telemonitoring with pharmacist management improves and maintains BP control

Imaxio receives FP7 grant to support the development of S. aureus vaccine

Study says screening heart with natriuretic peptide may reduce risk of dysfunction, heart failure

CTI announces publication of preclinical, clinical data for pacritinib in Drugs of the Future 2013

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News